MedTrace Logo

Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

NCT07693452 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-07-13

No results posted yet for this study

Summary

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Conditions

  • Appendiceal Mucinous Neoplasm
  • Pseudomyxoma Peritonei

Interventions

DRUG

Metformin

Given PO

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Oliver Eng, MD · Chao Family Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-18
Primary Completion
2028-02-29
Completion
2029-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07693452 on ClinicalTrials.gov